US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive immune system can lead to inflammation and scarring in various organs, including the pancreas, liver and kidneys.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Uplizna, given by infusion, is designed to bind to a protein located on the surface of B cells, the underlying inflammatory cause of IgG4-RD and other autoimmune conditions. "By removing or depleting these B cells throughout the body, both in the circulating blood and in the tissue, there's a chance for Uplizna to confer a real benefit," said Jay Bradner, Amgen's head of research and development.
Around 20,000 people in the U.S. suffer from the condition, he said.
The approval was based on data from a late-stage study in which Uplizna helped reduce the risk of flares by 87% compared to a placebo.
"This would be a fairly compelling drug that is infrequent, fairly safe, and very effective," TD Cowen analyst Yaron Werber told Reuters ahead of the decision.
Werber estimates Uplizna to generate global peak sales of $1.3 billion by 2030 for IgG4-RD alone.
Uplizna, which was already approved for a rare, severe neuroinflammatory disease called neuromyelitis optica spectrum disorder, brought in sales of $379 million in 2024.
Steroids — usually used to manage IgG4-RD — have many negative effects on patients, including mood changes, weight gain and osteoporosis, said Dr. Matthew Baker, associate division chief of immunology and rheumatology at Stanford University.
"The goal with a treatment like this is to definitely minimize steroid exposure, and I think it certainly will do that," Dr. Baker said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
6 hours ago
- Daily Mail
Report: White House meltdown over return of RFK Jr. aide
A staffer for HHS Secretary Robert F Kennedy Jr - who drew the ire of President Donald Trump's MAGA base and was fired - returned to his job last week after Chief of Staff Susie Wiles stepped in. Dr Vinay Prasad's unexpected return to the Food and Drug Administration (FDA) marks one of the more dramatic personnel reversals of the Trump administration. And some of Trump's MAGA allies, both in Washington and across the country, still have concerns about him and doubts about his loyalty. 'It seems to be amateur hour at the FDA, and Prasad is an unnecessary distraction,' a Trump official told the Daily Mail. A hematologist-oncologist and outspoken critic of FDA bureaucracy, Prasad has long argued that the agency is too slow to adapt to scientific innovation. In July, Makary told Politico that Prasad doesn't have a 'political bone to his body.' According to senior administration officials who spoke with Politico, Wiles worked closely with Kennedy and Makary to convince the president that Prasad was not anti-Trump and should be reinstated. 'I think it really is something good about the president that he's willing to change his mind when persuaded,' one of the senior administration officials told Politico. Still, Prasad's rehiring not only signals Trump's willingness to overlook past criticisms but also represents a quiet victory for Kennedy, who now has one of his most trusted allies back inside the agency. It also underscores the limits of Loomer's influence in shaping personnel decisions despite her past successes. She has reportedly been behind nearly a dozen ousts of so-called 'deep state' officials she says have been harmful to the administration. Trump reportedly fired multiple officials on the White House National Security Council after an April meeting with Loomer. But after Prasad's rehiring was announced, Loomer called the move 'demoralizing' and an 'open disrespect of the MAGA base.' Prasad's reinstatement places him at the center of one of the administration's most ambitious policy fights: reshaping how the US regulates vaccines and biotechnology. But in a column for Newsmax, Texas-based conservative strategist Charlie Kolean warned that Prasad's regulatory approach could slow the pace of medical innovation and delay life-saving treatments. He argued that Prasad's emphasis on excessive caution would create bottlenecks for biotech development, giving foreign competitors an advantage. And he told the Daily Mail that the FDA's direction on drug approvals and biotech regulation could shift under Prasad's leadership. During his initial stint at the FDA, Prasad blocked the approval of a gene therapy for Duchenne muscular dystrophy, citing concerns over the strength of the clinical evidence. The move sparked backlash from patient advocacy groups and families affected by the disease, who argued that the therapy represented a rare and urgent lifeline.
Reuters
7 hours ago
- Reuters
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
Aug 20 (Reuters) - The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' (RCKT.O), opens new tab gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares soared over 30% in morning trading on Wednesday. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
Reuters
8 hours ago
- Reuters
Fact Check: Statement from Namibian president rejecting Gates Foundation contraceptives trial is fake
Online claims that the Namibian president released a statement rejecting a proposal by the Gates Foundation to conduct trials of a contraceptive device are false. The claims followed an August 4 announcement, opens new tab by the Gates Foundation committing $2.5 billion to 'accelerate research and development on women's health' by 2030. This includes 'contraceptive innovation' and a focus on low- and middle-income countries, Reuters reported. An August 11 Facebook post, opens new tab attributed an 'official statement' to President Netumbo Nandi-Ndaitwah rejecting a supposed Gates Foundation proposal to conduct trials of a hormonal intrauterine device, designed to prevent pregnancy for up to eight years. 'Any attempt to hinder or suppress the growth of human potential in Namibia constitutes a grave injustice to our people and their future,' read the statement attributed to Nandi-Ndaitwah. TikTok posts, opens new tab made the same claim on August 12. On August 11, the X account linked to the Namibian presidency's official website labelled a screenshot, opens new tab of one of these posts as 'fake.' The presidency did not respond to Reuters' request for comment. The Gates Foundation told Reuters that it is 'not undertaking any H-IUD (hormonal intrauterine device) work in Namibia,' but that it does 'work with partners to expand access to trusted, voluntary options like H-IUDs in other countries.' The foundation added that the quote attributed to the president was 'fabricated,' saying that the presidency has 'dismissed the claims as unfounded,' referring to the post by the presidency's X account. Reuters found no statement rejecting any such trials published on the Namibian presidency's official website or associated social media channels. False. The Namibian president did not publicly reject a proposal by the Gates Foundation to conduct contraceptive trials. No such trial is taking place in Namibia, and the presidency said a statement attributed to Netumbo Nandi-Ndaitwah was fake. This article was produced by the Reuters Fact Check team. Read more about our fact-checking work.
